Latest articles and price-sensitive announcements with AI sentiment classification.
Neurizon said the June quarter was marked by rapid progress in Regimen I of its amyotrophic lateral sclerosis (ALS) platform ... Read More The post Neurizon reports Q4 milestones across pivotal ALS program and capital strategy appeared first on Stockhead.
Neurizon has completed enrolment in the ALS Platform Trial while securing new non-dilutive funding to support its clinical program. ... Read More The post Long Shortz with Neurizon Therapeutics: Milestones stack up for ALS program appeared first on Stockhead.
ALS posts record FY26 results with standout Minerals growth and advances in digital transformation. The post ALS FY26 results: Record growth, leadership moves, digital push appeared first on The Motley Fool Australia.
ALS Shares Make Green-to-Red YTD Move: What Comes Next? thebull.com.au
The final participant has completed their baseline visit and started treatment, completing enrolment into Regimen I. ... Read More The post Neurizon completes enrolment in pivotal ALS trial, topline results brought forward appeared first on Stockhead.
Highlights Neurizon Therapeutics has crossed a significant clinical milestone in its ALS development program. Recruitment and dosing progress continue to exceed expectations within the HEALEY ALS Platform Trial. The update places renewed attention on one of the more closely watched names in the Australian biotech sector. Neurizon Therapeutics has crossed the halfway dosing mark in its ALS trial program, highlighting continued clinical momentum and strong recruitment progress. Clinical milesto...
Neurizon has dosed 129 of 240 participants in Regimen I of the HEALEY ALS platform trial evaluating NUZ-001, with recruitment ... Read More The post Neurizon ALS platform trial passes 50pc dosing milestone ahead of schedule appeared first on Stockhead.
Highlights ALS shares declined ahead of the stock trading ex-dividend despite reporting a strong annual performance. The laboratory testing specialist is set to join the S&P/ASX 50 later this month. Investors continue focusing on dividend payments, index inclusion, and growth across commodities and life sciences testing. ALS remains under the spotlight as investors assess dividend payments, ASX 50 inclusion, and ongoing growth across commodities and life sciences testing operations. Austr...
Highlights ALS is approaching its ex-dividend date, putting renewed attention on its shareholder distribution profile. Earnings growth and dividend growth have remained supportive themes for the company in recent years. Dividend sustainability remains a key focus as payout levels continue to balance shareholder returns and business investment. ALS remains on dividend watchlists as its ex-dividend date approaches, supported by earnings growth, cash generation and diversified global operations....
Highlights ALS is approaching its upcoming ex-dividend date, making timing an important consideration for eligible shareholders. The company continues to demonstrate earnings growth alongside a long history of dividend increases. Dividend sustainability remains a key area of focus as payout levels continue to represent a significant portion of earnings. ALS is approaching its ex-dividend date with market attention focused on dividend sustainability, earnings growth and the company's diversifi...
ALS Limited (ASX:ALQ) Stock Goes Ex-Dividend In Just Four Days simplywall.st
Regimen I of Neurizon Therapeutics’ ALS Platform Trial will increase its total patient cohort by 50% to 240 participants. ... Read More The post Neurizon ALS trial expands cohort to 240 patients as enrolment accelerates appeared first on Stockhead.
How Investors Are Reacting To ALS (ASX:ALQ) Earnings And Its Strict 15% ROCE Deal Filter simplywall.st
Assessing ALS (ASX:ALQ) Valuation After Strong Full Year Earnings And EPS Growth simplywall.st
ALS (ASX:ALQ) Margin Improvement Challenges Bearish Narratives In FY 2026 Results simplywall.st
ALS Limited (ASX:ALQ) Falls Despite Record FY26 Profit: Buy the Dip or Wait? Stocks Down Under
Highlights Commodities-linked laboratory services remain central to mining operations. Resource activity continues shaping demand across testing and inspection sectors. Global industrial supply chains remain closely connected to commodities services. Australia’s commodities services sector continues attracting attention as mining infrastructure, laboratory testing, and industrial monitoring systems remain closely tied to global resource activity. Australia’s industrial and c...
ALS Ltd reported 10.7% revenue growth, a 25.8% rise in NPAT, stronger margins, and a higher dividend. The post ALS reports record FY26 earnings and dividend uplift appeared first on The Motley Fool Australia.
Assessing ALS (ASX:ALQ) Valuation After May 2026 Cyber Security Incident simplywall.st
Highlights New oral liquid ALS study cleared for Australian trial Liquid formulation aims to support treatment continuity Clinical development program continues to expand Neurizon Therapeutics is advancing its ALS drug development program after securing ethics approval for a new oral liquid study in Australia, supporting broader clinical progress and patient-focused treatment accessibility. Neurizon Advances ALS Research With New Clinical Milestone Australian biotech company Neurizon Th...
Highlights Strong upward movement observed across recent trading phases Elevated valuation multiples compared with broader sector peers Expansion momentum supported by laboratory testing demand across industries The industrial testing and inspection services sector plays a critical role in supporting environmental monitoring, mining services, food quality assurance, and life sciences. ALS Ltd, (ASX:ALQ), is a global testing and inspection services company that provides analytical, certi...
New preclinical data shows NUZ-001 increases activity of multiple protein clearance pathways in neuronal models. ... Read More The post Long Shortz with Neurizon Therapeutics: NUZ-001 builds momentum in ALS trial with new data appeared first on Stockhead.
Highlights Qantas (QAN), Brambles (BXB), and ALS (ALQ) show varying performance in the ASX 200 index. Industrial and transport sectors are active amid mixed market signals across ASX stock market. Key companies continue to influence investor attention within ASX mining stocks and broader ASX dividend stocks. Qantas, Brambles, and ALS impact industrial, transport, and inspection sectors, shaping activity across ASX 200, ASX 100, and broader ASX market trends. The ASX 200 index continues ...
Stockhead
Motley Fool
Google News
Kalkine